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incidence
The crude incidence of cervical cancer in the European Union
is 13.2/100 000 and the crude mortality rate is 5.9/100 000
women/year. Nearly 500 000 cervical cancer new cases are
occurring worldwide each year, responsible for 274 000 deaths.
Cervical cancer represents the third most common cause of
female mortality. The mortality is 10 times higher in developing
countries, where 80% of new cases occur, compared with
developed countries, since screening and treatment
programmes are frequently inaccessible to women in
developing countries. The screening capacity is satisfactory in
most European Union member states, even if, based on data
from available screening registers, the coverage of the screening
test is <80% in all programmes, ranging from 10% to 79%.
Early age at first sexual intercourse and early pregnancies have
been recently evidenced as risk factors for cervical cancer in
developing countries. High-risk persistent infection with
sexually transmittable human papillomavirus is responsible for
virtually all cases of cervical cancer. HPV-16 and HPV-18 are
the most prevalent of the oncogenic types. In addition to
screening techniques including conventional Papanicolaou
smear and HPV DNA testing, primary prevention via
vaccination against HPV is now available. The high efficacy of
the vaccines may dramatically decrease cervical cancer,
preventing up to 70% of newly diagnosed cases. The cost of the
vaccine, however, precludes its widespread implementation and
may increase the difference in mortality with developing
countries.
diagnosis
Pathological diagnosis should be made according to the World
Health Organization classification based on a surgical biopsy.
staging and risk assessment
Clinical examination represents the basis for Fe´de´ration
Internationale de Gyne´cologie et d’Obste´trique (FIGO)
classification, which is the most widely used classification. This
classification is based on tumoral extension, clinically assessed,
depending on tumour size, vaginal and/or parametrial
involvement, and bladder/rectum tumoral extension (Table 1).
FIGO classification has been recently reviewed and has
integrated sub-division in IIA tumours, based on clinical
tumour size assessment. FIGO classification requires basic
complementary examinations including chest X-ray and
intravenous pyelogram. Nowadays, magnetic resonance
imaging (MRI) is considered the reference complementary
examination as it is superior to computed tomography (CT)
scan for tumour extension assessment and equal to CT scan for
nodal involvement assessment. MRI should be preferred to CT
scan and include pelvic and abdominal imaging. MRI and CT
have low sensitivities for nodal involvement. Ultra-small
particles of iron oxide (USPIO), used as MRI contrast agent,
seem to improve sensitivity. USPIO is currently under
investigation by the Gynecology Oncology Group. Positron
emission tomography (PET) has been reported to have
sensitivity and specificity of 100% and 99%, respectively. PET is
still under evaluation, and is compared with surgical nodal
staging. A thoracic CT scan may be included for metastasis
assessment.
Surgical pelvic and para-aortic nodal staging are optional. In
early stage cervical cancer, sentinel node procedure is currently
under study. This technique seems to be a feasible method of
lymph node assessment with a high detection rate, and low
false-negative rate, and may even represent a more sensitive
procedure than pelvic lymphadenectomy.
Tumour risk assessment includes tumour size, stage, nodal
involvement, lymphovascular space involvement and
histological subtype. Squamous cell carcinoma is the most
frequent histological type, accounting for 80%–90% of the
cancers. Adenocarcinoma represents 10%–20% of cervical
cancer histologies, with an increase in relative distribution of
adenocarcinoma compared with squamous cell carcinoma in
developed countries. Adenocarcinoma has significantly lower
survival rates compared with squamous cell carcinoma stage to
stage, with higher distant failure rates.
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treatment
Multidisciplinary treatment planning is mandatory, based on
tumour size and extension.
FIGO stage IA1
Standard treatment consists of conization with free margins or
simple hysterectomy (according to patient age). In case of
lympho-vascular space involvement, pelvic lymphadenectomy
is recommended. In patients with at least two high-risk factors
(deep stromal invasion, lymphovascular space involvement,
large primary tumours) postoperative pelvic radiotherapy with
or without concomitant chemotherapy should be considered.
In patients with positive margins, parametrial involvement or
pelvic node involvement, standard treatment consists of
complementary concomitant chemoradiation.
FIGO stage IA2
Surgery is the standard. Options consist of conization or
trachelectomy in young patients and simple or radical
hysterectomy in other patients. Pelvic lymphadenectomy is
required. In patients with positive margins, parametrial
involvement or pelvic node involvement, standard treatment
consists of complementary concomitant chemoradiation.
FIGO stage IB1
There is no standard treatment. Options consist of surgery,
external irradiation plus brachytherapy or combined radio-
surgery.
Standard surgery consists of radical hysterectomy, bilateral
oophorectomy and pelvic lymphadenectomy. Conservative
fertility-sparing surgery can be proposed in young patients with
tumour presenting excellent prognostic factors, consisting of
radical trachelectomy. Potential candidates are patients with
tumours having largest diameter of <20 mm, without
lymphovascular space involvement and without lymph node
involvement. A review of 548 patients treated with radical
trachelectomy and lymphadenectomy reported a recurrence
rate of 5%, in accordance with what has been reported for
standard colpohysterectomies. Pregnancy outcomes were
reported to be within the range 41%–78%. These data however,
do not represent a Level I of treatment evidence.
Combined radio-surgery, which represents a therapeutic
option, usually consists of preoperative brachytherapy followed
6–8 weeks later by surgery. In patients treated with upfront
surgery presenting positive margins, disease within parametria
or pelvic node involvement, standard treatment consists of
complementary concomitant chemoradiation.
FIGO stage IB2–IVA
Concomitant chemoradiation represents the standard. This
modality is superior to radiotherapy alone for local control,
metastasis rate, disease-free and overall survival. A meta-
analysis was recently performed, based on 18 trials with
individual patient data, collecting a total of 3452 patients.
Cisplatin-based chemotherapy was used in 85% of the patients.
The results demonstrated a 6% improvement in absolute 5-year
survival (from 60% to 66%) and 8% improvement in 5-year
disease-free survival with chemoradiotherapy. A larger benefit
was seen in two trials in which chemotherapy was given after
chemoradiotherapy with an absolute improvement of 19% at 5
years. Patients with advanced stage IB2–IIA/B may benefit more
from chemoradiotherapy than patients with stage III and IVA,
translating to a 5-year survival benefit of 10% for women with
stage IB–IIA, 7% for women with stage IIB and 3% for women
with stage IIIB–IVA. Non-platinum-based regimens for
chemoradiation appear to be as efficient as platinum-based
chemotherapy. The most common regimen, however, is
cisplatin monotherapy 40 mg/m2 on a weekly schedule.
Chemoradiotherapy increases acute toxicity, particularly
gastrointestinal and haematological side-effects. Late effects of
this combined treatment have not been extensively studied in
the literature. The role of adjuvant chemotherapy after
concomitant chemoradiation remains unclear and should be
included in further clinical investigations. One randomized
Table 1. FIGO staging
0 Carcinoma in situ (preinvasive carcinoma)
I Cervical carcinoma confined to the uterus;
invasive carcinoma diagnosed by
microscopy
IA All macroscopically visible lesions—even
with superficial invasion—are stage IB
IA1 Stromal invasion £3.0 mm in depth and
£7.0 mm in horizontal spread
IA2 Stromal invasion >3.0 mm and £5.0 mm
with a horizontal spread £7.0 mm
IB Clinically visible lesion confined to the
cervix or microscopic lesion greater
than IA2
IB1 Clinically visible lesion £4.0 cm in greatest
dimension
IB2 Clinically visible lesion >4.0 cm in greatest
dimension
II Tumour beyond the uterus but not to
pelvic wall or to lower third of the
vagina
IIA without parametrial extension
IIA1 clinically visible lesion £4.0 cm in
greatest dimension
IIA2 clinically visible lesion >4.0 cm in
greatest dimension
IIB with parametrial extension
III Tumour extends to pelvic wall and/or
involves lower third of the vagina and/
or with hydronephrosis or non-
functioning kidney
IIIA Tumour involvement of the lower third of
the vagina without extension to the
pelvic wall
IIIB Tumour extension to the pelvic wall and/
or causes hydronephrosis or non-
functioning kidney
IVA Tumour involvement of rectal and/or
bladder mucosa and/or extends beyond
true pelvis
IVB Distant metastasis
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study has recently been presented showing the benefit of
adjuvant chemotherapy with cisplatin–gemcitabine after
concomitant chemoradiation.
The use of recombinant human erythropoietin to increase
haemoglobin levels in the context of concomitant
chemoradiation within the frame of a randomized study failed
to show any therapeutic ratio, as the trial was prematurely
closed, due to an excess of thromboembolic events in the
erythropoietin arm. Less than 25% of the planned patients had
entered the study and the difference in thromboembolic events
was not statistically significant between the two randomized
arms.
External irradiation is combined with brachytherapy and the
total treatment duration should remain <55 days. MRI 3-D
based brachytherapy seems to improve local control.
Complementary extra-fascial hysterectomy after radiotherapy
has been evaluated within the frame of a randomized trial by
the RTOG group. There was no survival difference between the
two arms, with a potential benefit among patients with
persistent disease. This complementary surgery can therefore be
considered as an option for patients with persistent disease.
Neoadjuvant chemotherapy remains controversial and is
currently under investigation by the EORTC (55994). A
systematic review with individual patient data meta-analysis has
demonstrated the superiority of neoadjuvant chemotherapy
followed by surgery over radiotherapy in terms of overall
survival. In spite of these results, neoadjuvant chemotherapy
has not been considered as a standard for two reasons: one is
the inferiority of the control arm (radiotherapy alone)
compared with the present standard of concomitant
chemoradiation arm in this meta-analysis and second is the
results of the GOG 141 study, showing no advantage of
neodjuvant chemotherapy with vincristine and cisplatin before
radical hysterectomy and pelvic/para-aortic lymphadenectomy
in bulky stage IB.
FIGO stage IVB
Platinum-based combination chemotherapy has a potential
benefit. A statistically significant benefit on median overall
survival, median progression-free survival, and overall response
rate was evidenced with a combination of cisplatin plus
topotecan, compared with cisplatin alone in a randomized trial
conducted by the GOG. Another randomized trial conducted
by the GOG compared four cisplatin doublets. No regimen was
superior to cisplatin and paclitaxel. Although this regimen
showed a trend in favour of response rate and progression-free
survival, there were no statistically significant differences.
Differences in chemotherapy schedules should take into
account pre-existing morbidity and potential toxicity for
individualized treatment.
locoregional and metastatic recurrence
For most patients palliative chemotherapy is the standard
option. Pelvic surgery (exenteration in most cases) is an option
in selected cases of central pelvic recurrence. Salvaged
radiotherapy should be considered as an option for patients
with pelvic recurrence without prior irradiation.
follow-up
The most appropriate follow-up strategy has not been clearly
stated. Clinical with gynaecological examination including PAP
smear are usually performed every 3 months for the first 2
years, every 6 months for the next 3 years and yearly thereafter.
SCC dosage in squamous cell carcinoma may be useful in
patients’ follow-up if initially increased. PET/CT might have
a role in early local recurrence and metastasis detection.
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